Contact Information
Manon Levesque
Departmental Secretary of Pathology and Laboratory Medicine
451 Smyth road,
Room 4155
Ottawa, Ontario
CANADA K1H 8M5
Telephone: 613-562-5422
Fax: 613-562-5442
e-mail: mlevesq2@uottawa.ca

Sheila Schnupp
Office and Residency Program Administrator (Anatomical and General Pathology)
Telephone: 613-562-5800 x8342
Fax: 613-562-5442
e-mail: sschnupp@uottawa.ca

John P. Veinot, M.D., F.R.C.P.C (Canada)
Chairman, Department of Pathology and Laboratory Medicine
Tel: 613-562-5422
Fax: 613-562-5442
E-mail: sschnupp@uottawa.ca

Back to Faculty of Medicine Staff page.

Manijeh Daneshmand

Manijeh Daneshmand

M.D.   Specialist in Pathology, (University of Tehran, Iran),
Medical Diploma  (Azad University of Tehran, Iran)

Assistant Professor, Department of Pathology and Laboratory Medicine, Faculty of Medicine
Senior Research Associate and GLP Facility Manager, Ottawa Hospital Research Institute, Division of Cancer Therapeutics

Telephone:  (613) 737 7700  Ext.70346
Fax: (613) 247 3524
E-mail:  mdaneshmand@ohri.ca


Areas of Laboratory Expertise

  • Cancer cell genetics
  • Molecular pathology
  • Laser capture microdissection

Reseach Interests

  • Correlative studies for cancer clinical trials (small molecules, oncolytic viruses)
  • Cancer genetics
  • Cancer translational research


Recent Publications

  • Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial, Byeong-Ho Park, Taeho Hwang, Ta-Chiang Liu, Daniel Y Sze, Jae-Seok Kim, Hyuk-Chan Kwon, Sung Yong Oh, Sang-Young Han, Jin-Han Yoon,Sook-Hee Hong, Anne Moon, Kelly Speth, Chohee Park, Young-Joo Ahn, Manijeh Daneshmand, Byung Geon Rhee, Herbert M Pinedo, John C Bell, David H Kirn, Lancet Oncol. 2008 Jul
  • Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow, Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, Stojdl DF, Daneshmand M, Speth K, Kirn D, McCart JA, Atkins H, Bell JC, Mol Ther. 2007
  • Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands, Mark Agulnik, Ezra W.E. Cohen, Roger B. Cohen, Eric X. Chen, Everett E. Vokes, Sebastien J. Hotte,Eric Winquist, Scott Laurie, D. Neil Hayes, Janet E. Dancey, Shirley Brown, Gregory R. Pond, Ian Lorimer,
    Manijeh Daneshmand, James Ho, Ming-Sound Tsao, and Lillian L. Siu,
    Journal of Clinical Oncology, 2007
  • Erlotinib in lung cancer - molecular and clinical predictors of outcome, Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Lui N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA., N. Eng J Med, 2005
Back to Faculty of Medicine Staff page.
For additional information, consult our list of contacts
Technical questions? medtech@uottawa.ca
Last updated: 2012.06.19